Medivir (LSE:0GP7) - Aandelenkoers, Nieuws & Analyse

0GP7 Overzicht aandelen

A pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. Meer informatie

0GP7 fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 58.84% per jaar groeien

Risicoanalyse

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Heeft een omzet van minder dan 1 miljoen USD ( SEK8M )

Aandelen zijn zeer illiquide

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

+ 1 meer risico

Medivir AB (publ) Concurrenten

Oncimmune Holdings

AIM:ONC

UK£17.2m

OptiBiotix Health

AIM:OPTI

UK£12.2m

Tissue Regenix Group

AIM:TRX

UK£40.6m

Aptamer Group

AIM:APTA

UK£6.5m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Medivir
Historische aandelenkoersen
Huidige aandelenkoers	SEK 2.93
52 Week Hoogtepunt	SEK 7.35
52 Week Laag	SEK 2.93
Bèta	-0.17
11 maand verandering	0%
3 maanden verandering	n/a
1 Jaar Verandering	-58.19%
33 jaar verandering	-64.70%
5 jaar verandering	-84.69%
Verandering sinds IPO	-95.12%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	0GP7	GB Biotechs	GB Markt
7D	0%	2.0%	1.7%
1Y	-58.2%	-17.5%	8.3%

Rendement versus industrie: 0GP7 presteerde slechter dan de UK Biotechs -sector, die het afgelopen jaar een rendement van -17.5 % opleverde.

Rendement versus markt: 0GP7 presteerde slechter dan UK Market, dat het afgelopen jaar een rendement van 8.3 % opleverde.

Prijsvolatiliteit

Is 0GP7's price volatile compared to industry and market?
0GP7 volatility
0GP7 Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.7%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stabiele aandelenkoers: 0GP7 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van 0GP7 in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1987	10	Jens Lindberg	www.medivir.com

Medivir AB (publ) Samenvatting

Hoe verhouden de winst en inkomsten van Medivir zich tot de beurswaarde?
0GP7 fundamentele statistieken
Marktkapitalisatie	SEK 348.84m
Inkomsten(TTM)	-SEK 96.52m
Inkomsten(TTM)	SEK 7.73m

45.1x

P/S-verhouding

-3.6x

Koers/Winstverhouding

Is 0GP7 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
0GP7 resultatenrekening (TTM)
Inkomsten	SEK 7.73m
Kosten van inkomsten	SEK 76.47m
Brutowinst	-SEK 68.73m
Overige uitgaven	SEK 27.79m
Inkomsten	-SEK 96.52m

Laatst gerapporteerde inkomsten

Mar 31, 2024

Volgende inkomensdatum

Aug 22, 2024

Winst per aandeel (EPS)	-0.86
Brutomarge	-888.81%
Nettowinstmarge	-1,248.18%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde 0GP7 op de lange termijn?

Bekijk historische prestaties en vergelijking

0GP7 Overzicht aandelen

Beloningen

Risicoanalyse

Medivir AB (publ) Concurrenten

AIM:ONC

UK£17.2m

AIM:OPTI

UK£12.2m

AIM:TRX

UK£40.6m

AIM:APTA

UK£6.5m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Medivir AB (Publ) Appoints Nomination Committee

Medivir Presents Positive, Mature Data from its Ongoing Phase 1b / 2a Study of fostroxacitabine bralpamide (fostrox) + Lenvima in Advanced Liver Cancer (hepatocellular carcinoma/HCC) at the European Society of Medical Oncology Congress

Medivir AB to Present Mature Clinical Data for Fostrox + Lenvima at ESMO Conference

Medivir AB (publ) to Report First Half, 2025 Results on Aug 21, 2025

Medivir AB to Present Updated Clinical Data for Fostrox + Lenvima in Hepatocellular Cancer At ESMO Conference in September Stockholm

Medivir AB Presents Positive New Data from Its Ongoing Phase Ib / IIa Study of Fostroxacitabine Bralpamide (Fostrox) + Lenvima® in Advanced Hepatocellular Carcinoma (HCC)

Recent updates

Medivir AB (Publ) Appoints Nomination Committee

Medivir Presents Positive, Mature Data from its Ongoing Phase 1b / 2a Study of fostroxacitabine bralpamide (fostrox) + Lenvima in Advanced Liver Cancer (hepatocellular carcinoma/HCC) at the European Society of Medical Oncology Congress

Medivir AB to Present Mature Clinical Data for Fostrox + Lenvima at ESMO Conference

Medivir AB (publ) to Report First Half, 2025 Results on Aug 21, 2025

Medivir AB to Present Updated Clinical Data for Fostrox + Lenvima in Hepatocellular Cancer At ESMO Conference in September Stockholm

Medivir AB Presents Positive New Data from Its Ongoing Phase Ib / IIa Study of Fostroxacitabine Bralpamide (Fostrox) + Lenvima® in Advanced Hepatocellular Carcinoma (HCC)

Medivir Selects Global CRO Partner for Upcoming Phase 2B Study in HCC with fostrox + Lenvima and Initiates Study Feasibility

Medivir Aktiebolag (publ) Approves Board Appointments

High number of new and inexperienced directors

Full year 2023 earnings released: kr1.48 loss per share (vs kr1.59 loss in FY 2022)

High number of new and inexperienced directors

Medivir AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

Medivir AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 20.000001 million.

High number of new and inexperienced directors

Medivir AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 20.000001 million.

Medivir Presents the First Clinical Data with Fostrox + Lenvima At the Asco GI Scientific Congress

Medivir AB Announces Further Improved Clinical Benefit with Fostrox + Lenvima as Data from the Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancer

Medivir AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 128.961315 million.

Medivir AB Announces Data from Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancers

Medivir AB Announces Updated Formulation of Fostrox Critical to Support Planned Study with Accelerated Approval Intent in Second Line HCC

Medivir AB Announces Updated Formulation of Fostrox Critical to Support Planned Study with Accelerated Approval Intent in Second Line HCC

Medivir AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 147.979713 million.

Third quarter 2023 earnings released: kr0.42 loss per share (vs kr0.27 loss in 3Q 2022)

Medivir AB (publ) to Report First Half, 2024 Results on Aug 22, 2024

High number of new and inexperienced directors

Medivir AB (publ) to Report Q1, 2024 Results on Apr 30, 2024

Medivir AB (publ), Annual General Meeting, May 07, 2024

Medivir AB (Publ) Announces Resignation of Anette Lindqvist as Director

Medivir AB Announces All Patients in the Ongoing Phase 2A Study in Advanced Hepatocellular Car Car Car Carcinoma Has Now Dosed At Least Two Treatment Cycle

Medivir AB Reports Promising Interim Data, Including A First Complete Response in Phase 1B/2A Hcc Study with Fostrox in Combination with Lenvima

Medivir AB Announces 15th Patient with Advanced Liver Cancer Has Been Included in the Ongoing Phase 2A Study

Medivir AB Announces Formation of A Scientific Advisory Council

Medivir AB Announces Patent Application for Fostrox Approval in China

New major risk - Revenue size

Medivir AB Completes the Dose Escalation Part (Phase 1B) of the 1B/2A Study in Hcc and Focus on the Combination of Fostrox and Lenvima

Medivir Completes A Successful Pre-IND Meeting with the FDA

Medivir AB (Publ) Appoints Pia Baumann as New Chief Medical Officer

Medivir AB (Publ) Appoints Nomination Committee

Medivir AB (publ) to Report Q2, 2023 Results on Aug 18, 2023

Medivir AB (publ) to Report Q1, 2023 Results on Apr 27, 2023

Medivir Aktiebolag (Publ) Announces Board Changes

Medivir AB (publ) to Report Fiscal Year 2021 Final Results on Apr 05, 2022

Medivir AB (Publ) Announces Phase II Study of Miv-711 for Osteoarthritis Shows Statistically Significant Reduction in Oa Pain

Medivir AB (publ) Announces Abstract for MIV-818 phase 1b monotherapy for ESMO Congress published

Medivir AB Announces Positive Data from the Remetinostat Phase II Study in Basal Cell Carcinoma Published in Clinical Cancer Research

Medivir Announces the Design of its Upcoming MIV-818 Combination Study

Medivir AB Announces Positive Results from Investigator-Initiated Phase II Clinical Study of Remetinostat in Patients with Squamous Cell Carcinoma

Medivir AB (publ), Annual General Meeting, May 05, 2021

Medivir AB Announces Delisting of Paid Subscription Shares

Medivir AB Enters into Licensing Agreement with Ubiquigent Limited for Preclinical Program USP7

IGM Biosciences, Inc. Enters into Exclusive Licensing Agreement with Medivir for Birinapant

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Medivir AB (publ) Samenvatting

45.1x

-3.6x

Inkomsten en omzet